Join ACTIV-H at CPHI Milan 2024! We’re pleased to be present at the next CPHI Milan event from October 8-10, 2024! Meet Dr Zahra ABADA, our CEO, to discover how ACTIV-H unique technology and expertise can help accelerate your pipeline and propel your early drug discovery projects forward. 📅 Schedule a short meeting here : zahra.abada@activ-h.com At ACTIV-H, we specialize in delivering novel molecules and enhancing the chemical diversity for our clients. Our cutting-edge services and technology, rooted in (super)acid chemistry and advanced flow technology, pave the way for unparalleled molecular diversity. This innovative approach enables direct and selective transformations that are unattainable through traditional methods. "Offering new alternatives in the service of health is essential" says Prof. Sébastien Thibaudeau, co-founder and CSO of ACTIV-H. ''Our chemical diversification offer is a new option, and our R&D program opens up concrete perspectives in this field." What We Offer •Access to unique molecules with a complemetary and powerful toolbox •Explore new chemical and IP spaces •A unique mode of molecular activation targeting Inert or metabolically sensitive positions •Revitalizing Existing molecules by unlock new possibilities in drug discovery We look forward to meeting you in this exciting italian edition 'at the heart of Pharma’ and explore how our unique platform can benefit your projects. See you there! #CPHIMilan #PharmaEvent #Research #deeptech #Networking #Innovation #PharmaIndustry #SmallMolecules
ACTIV-H’s Post
More Relevant Posts
-
Foxx Life Sciences Featured in Ingredients South Asia! Discover how we're revolutionizing laboratory and biotech solutions with our innovative products! 📍 Visit their booth in CPHI PMEC: Hall 5, Booth J01 📖 Grab Your Copy: Check out our exclusive feature in Ingredients South Asia and learn more about our latest advancements. #FoxxLifeSciences #IngredientsIndia #BiotechInnovation #LaboratorySolutions #cphi
-
-
🎉 In two weeks, we’re preparing something truly interesting and, I hope, valuable for Ukrainian science, so I want to share. On September 17-20, together with our partners from the IMBG, we’re hosting the first conference in Ukraine dedicated to next-generation therapy development - the BioGENext Conference. About a year ago, we at YP Biotech came up with the idea to organize an event that would bring together everyone working in the field of biomedicine: scientists, industrial R&Ds, educators, students, technology transfer specialists, patenting experts, and regulatory professionals. The goal was to unite them for collaboration, partnerships, and industry development, because we are convinced: together, we are much stronger. And what could unite them better than the opportunity to discuss innovations in biomedicine and the development of next-generation drugs, share their experiences, and hear the thoughts of their colleagues? This is how the BioGENext Conference was born. After 9 months of active preparation, we created the conference platform, received and reviewed about 100 abstracts for publication, and more than 300 scientists, biotechnologists, and students have registered to participate in various formats. We’ve put together a program we’re proud of. Our speakers are world-leading experts in RNA therapy development and recombinant proteins, gene editing and bioinformatics, biomarkers and molecular diagnostics. There are only 2 weeks left, and we invite everyone interested in innovations, biomedical research, and the future of medicine. Register, come and see. It will be engaging, scientific, and for the first time in forever - a chance to meet in person in a modern, comfortable space, share ideas, explore opportunities for work and joint projects, and get inspired. https://lnkd.in/ed_3Vxav See you at the BioGENext Conference!
As the event approaches, we invite you to join BioGENext Conference on September 17-20 to experience all benefits of on-site participation! Program Highlights: ☑️ Leading Expert Talks: Gain insights from top experts in the field. ☑️ Workshops: - Grant Opportunities in Biomedical Research - The Path of Innovation from Research to Production - CRISPR Basics ☑️ Consulting & Training Zone: Receive expert advice from AcademCity, BionixLab, Biolabtech, and more. ☑️ Panel Discussion: Participate in a pivotal discussion on “Creating a strategy for the development of the biomedical and biopharmaceutical research ecosystem in Ukraine: A Synergistic Approach”. ☑️ Networking & Comfort: Enjoy a secure, well-equipped venue perfect for networking and communication. ☑️ Stable power supply: You don't need to worry about electricity outages and internet connection. 👉 Explore the program and register here: https://lnkd.in/dAJ4wXnY We look forward to welcoming you to the BioGENext Conference!
-
Chemistry Today issue 5 is out and will be present at CPHI and #SPICA symposium⤵ 🔗online version: https://lnkd.in/eJiX_wKZ 👀What you will find: ➡#CDMO: Helena Bayley, Analyst, EMEA Thought Leadership at IQVIA, explores how global spending on medicines and volume use will change in the coming years, and the implications for contract development and manufacturing organisations (CDMOs). ➡#Digitalization: a great section with several contributions with insights into its potential in the pharma industry - take a look at the topics below: Martin Mayer (ZETA GmbH), Selma Celikovic (Graz University of Technology), Jakob Rehrl (Salzburg University of Applied Sciences): From engineering to operations: addressing pharma challenges by digital approaches Luke Tregilgas (Haley Guiliano LLP): The evolving patent landscape at the intersection of biotechnology, pharmaceuticals, and artificial intelligence Rene Fischer, Mohammad Ghazanfar Ali Danish (Fraunhofer IESE): Towards individualized medicine: embracing digital twins and digital dependability in pharma 4.0 Wieser Elke (VTU Österreich), Stefan Pauli (VTU Engineering Schweiz AG) Bridging AI and GMP standards in the future of pharma ➡Preparative Chromatography: ahead of the SPICA symposium in Milan on October 15-18, this peer-reviewed contribution explores novel purification strategies for lipid nanoparticles building blocks. Written by the CordenPharma Switzerland team: Alexander Klaiber, Uwe Albrecht, Markus Juza. 📖Other topics: #HPAPIs, #PrecisionMedicine, #SpecialtyChemicals, #PatientCentricity, #Biocatalysis, #Sustainability Visibility: issue 5 will be distributed at CPHI and #SPICA symposium in Milan (organised by LD Organisation - Scientific Conference Producers) Supporters: Jiuzhou Pharma/九洲药业, FARAVELLI , Olon, WuXi Chemistry, Veranova, SINOCOMPOUND, Stevanato Group, Neuland Laboratories Limited, Cerbios-Pharma SA, FAGGI ENRICO SPA, amita health care, EPO Srl - Estratti Piante Officinali, Farmhispania Group, Angelini Pharma, Enzymaster Deutschland GmbH, Indena, CPHI, MarketChemica & Associates , IBSA Group, UQUIFA, Bormioli Pharma, PROCOS S.P.A. (CBC Group) Other authors in the comments below⤵ Enjoy the issue! #ChemistryToday #WeAreTKS
-
-
Vishal Pathade will be at the International Conference on Pharmacometrics (ICOP) 2025 in Manipal on February 1-2. The event will bring together experts from industry and academia to discuss the latest trends shaping pharmacometrics—a field that applies mathematical modelling to optimize drug development and therapeutic strategies. The conference will provide an opportunity to engage with thought leaders, explore emerging methodologies, and strengthen collaborations that drive innovation in this space. #sailifesciences #drugdiscovery #ICOP2025 #Pharmacometrics
-
-
“The most crucial step in scaling up your chromatographic methods is always the R&D phase.” Join Matthias Käseborn and our team of experts at CPHI, Milan this October to discuss your drug discovery and scale-up challenges! Learn more about our presence at CPHI and book a meeting with our experts here: https://hubs.ly/Q02PQ8wQ0
-
Next week, our team is heading to Barcelona for Drug Discovery Chemistry Europe. Focusing on the challenges of discovering and optimising small molecule drug candidates, the event will address the practical issues of drug discovery using innovative chemical tools and approaches. As part of the conference, Cambridge Healthtech Institute will bring together experts to discuss new developments and opportunities at their inaugural Next-Gen Degraders & Molecular Glues. PROTACs and molecular glues are unlocking previously overlooked ligases and degradation pathways to target the undruggable for therapeutic intervention. GlueSEEKER is Phoremost’s phenotypic screening platform designed to accelerate the discovery of novel molecular glues. Catch Alberto Moreno de la Gándara’s presentation on Day 1 to learn more: 📆 3rd Dec, 9:30am CET 🎤 Molecular Glue Discovery by High-throughput Neomorphic Remodelling of Effector Proteins For the full agenda and more information on other tracks, visit ➡️ https://lnkd.in/eMRAHb6n #DDCEurope #DrugDiscovery #MolecularGlues
-
-
📢 I’m thrilled to share that I’ll be speaking at the #Pharmalab Congress in Düsseldorf on November 26th at 5 PM! My talk will focus on a fascinating and complex topic: 🦠“Detection and Quantification of #Endotoxic (or Not Endotoxic) #Lipopolysaccharides.” Here’s a sneak peek at what I’ll be diving into: 🔬The incredible molecular diversity of lipopolysaccharides (#LPS) 🧪A comparison of key detection and quantification methods: ▶️#LAL assay ▶️#HEK-blue #TLR-4 ▶️LC-MS/MS ▶️#MALDI-MS ️⚡Exploring the structure-activity relationship of LPS. 💡Debunking myths: Not all lipopolysaccharides are toxic! If you’re attending Pharmalab, I’d love for you to join me or my colleagues Elodie TRAN and Stephanie Harfouche! Let’s connect, exchange ideas, and dive into the science together.
-
-
One week after the #ECM2024 conference, and I am still buzzing with excitement from all the stimulating talks that were held. I have primarily worked on immune cells in infectious diseases, and had a small stint working on fibroblasts as my first job after my masters. I managed to connect with two old colleagues from those days, and see all the work they and their teams have been working on for the last two decades. Whilst cells are important in health and disease, the structure that maintains the tissues holds valuable information for disease stratification, disease progression, responsiveness to treatment, and many other aspects of disease pathology and response. The potential in measuring matrix proteins and observing the patterns of expression, we can learn a lot about patient populations and the heterogeneity there is. We are not clones, not every person responds the same. Understanding our differences and similarities can help pharma screen for the right patients, and identify populations that need novel therapeutics. I am a convert. The matrix is the most fascinating and important structure in understanding pathologies and finding solutions. 😉 Watch the video to get inspired for 2026, then book your tickets and join us! The Extracellular Matrix Pharmacology Congress #science #ExtraCellularMatrix #ECM2026 #pharmacology #drugdiscovery
”Some people in this room will think tissue destruction is the most important thing. Other people in this room will think tissue formation is the most important thing. And I think this is exactly why we have conferences,” said #ECM2024 Chair Morten Asser Karsdal in his opening speech at The Extracellular Matrix Pharmacology Congress last week in Copenhagen. Head of Conference Organisation at CAP Partner Hanne Kvalheim agrees and reflects: “In its essence, organising scientific conferences is about creating this special space for sharing and discussing science where everyone goes home inspired. And I think ECM this year was a good example of that. ” Sponsorship and Exhibition Director at CAP Partner Katerina Vicen agrees that the conference was a success. “I often think organising the second edition of a conference is more difficult than organising the first one. The novelty is gone, and the expectations are higher. But in my opinion, ECM succeeded in giving participants, sponsors, and exhibitors the conference experience they came for – and a little more.” A thank you shout out to our many collaboration partners in making this conference a reality! ECM, Nordic Bioscience, Tivoli Hotel & Congress Center A/S Holmud fielddrive Conference highlights video below is produced by ZoomDox - Fasthold budskabet. #pco #reflections #conferenceorganising #copenhagen #scientificconferences #drugdiscovery #pharmacology
-
New passport (finally) arrived ! Ready to go. Join me and my colleagues Maria Pia Catalani and Alessandro Cinti at BOOTH 410 to discuss the latest innovations in drug discovery and the way Axxam might support your next Research program. But that's not all! Don’t miss Alessandro’s 30-minute talk on Targeted Protein Degradation (TPD): A New Frontier in Drug Discovery: 🧬 Abstract: Targeted Protein Degradation (TPD) offers a novel approach to modulate the intracellular levels of disease-causing proteins. Here, we will delve into the practical aspects of TPD, focusing on the development and implementation of cell-based assays aimed at monitoring target protein levels, and will discuss how complementary cell-based and cell-free assays support the discrimination of unspecifically-interfering compounds and detailed characterization and further development of hit compounds. 📅 Date: October 2, 2024 📍 Location: Boston, MA, USA #DiscoveryOnTarget2024 #DoT #TargetedProteinDegradation #TPD #Innovation #DrugDiscovery
-
-
Psy Data Juggler | AI & Big Data Analysis | Data Scientist | Happy to follow/connect 😀 | Networking brings the world closer 💫 |
A great resource and raw data's are even more useful once decrypting them.
🔎 🤔 What is Open Targets? Our recent review is a crash course in how we came to be, the science that we do, and the impact of this industry-academia collaboration on our partners and the community. 👉 https://lnkd.in/e6q9WqMp Pictured below is an illustration of the Open Targets project framework, with an example of a research project — Project Score — showing the emergence and journey of a potential target lead through the workflow. We bring together publicly available data with data generated through the collaborative research program’s projects to provide causal evidence for target-disease associations as well as foundational knowledge related to genes and diseases. This knowledge is integrated into our open-source informatics platforms, and potential targets are fed into our validation lab for further mechanistic insights. At each step, the workflow feeds into our industry partners’ drug discovery pipelines, and, once publicly available, into the wider scientific and drug discovery community, with the ultimate aim of helping to develop safer and more effective medicines.
-
